Summit Therapeutics Share Discussion Threads

[chrisatrdg] 15/5/2017 12:25

Got your drift freedosh would be good to move up to the next level & agree with waterloo01 good that RNS earlier than being suggested by SRPT recent comments.

At present only up 10p per Barclays Stockbrokers 5.63% hopefully more to come - currently share price is 'woefully low'.

[freedosh] 15/5/2017 12:18

Inverted shoulder completed. Should rocket to 250p now.
No advice intended! GLA

[waterloo01] 15/5/2017 12:16

24 wk MRI and function data from all 40 alongside biopsy data from 20 in 1st Q 18. Great to get milestone earlier than expected (based on SRPT comments) and look forward to RDZ update before the summer!

[football] 15/5/2017 12:04

best bit- Summit to Receive $22 Million Milestone Payment

[hugus maximus] 15/5/2017 12:02

Hurrah! RNS Summit to Receive $22 Million Milestone Payment .... SUMMIT COMPLETES ENROLMENT OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS

[luminoso] 14/5/2017 17:08

Shameless, blatant plug - while waiting for news, might be worth casting an eye over N4P, which awoke from its slumber on friday..........I'll get my coat.

[hugus maximus] 12/5/2017 16:52

zzzzZZZZZZ

[football] 12/5/2017 14:45

Can't believe it's over a week without a post here let's hope for some news so we have something to post about

[luminoso] 05/5/2017 13:26

Must have been an advfn glitch, football. Like you, I saw the price was up 5p or so first thing this morning but now no record of it.

[football] 05/5/2017 08:09

news at 12 seeing the share price is up

[chrisatrdg] 04/5/2017 13:35

Recent SEC Submission as per previous years:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 27, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Summit Therapeutics plc

File No. 001-36866 - CF#34960
_____________________

Summit Therapeutics plc submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on March 30, 2017.

Based on representations by Summit Therapeutics plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 4.23 through October 3, 2026
Exhibit 4.24 through December 4, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary

[football] 03/5/2017 08:33

youtube video 2/5/17



Publishing of Phase II ridinilazole study in Lancet 'a significant achievement' for Summit

[hugus maximus] 03/5/2017 08:24

RDZ v FDX results ... ETA?

[gersemi] 02/5/2017 07:10

Another Mofit Bio it seems but far better, it seems

'The results showed ridinilazole demonstrated substantial clinical benefit over vancomycin'..this is a game changer

Iclaprim can only demonstrate an equal degree of efficacy

[chrisatrdg] 01/5/2017 21:30

Sarepta Therapeutics May Attract Activist Attention



Makes for interesting reading I wonder where Summit would fit in this or not?

[hugus maximus] 29/4/2017 12:12

Although there is discussion of the move toward Phase 3, in both the above and Lancet pages, there is a strange absence of any reference to RDZ v FDX trial? (Or have I missed something?)

Does anyone have a notion of when this data is finally going to be made available?

[football] 29/4/2017 00:55

link above

Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Stati...

28/04/2017 11:30pm
GlobeNewswire Inc.


Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection (‘CDI’), announces the online publication of results from the Company’s Phase 2 clinical trial, called CoDIFy, in The Lancet Infectious Diseases. CoDIFy evaluated the Company’s novel antibiotic for the treatment of CDI, ridinilazole, against standard of care, vancomycin. The results showed ridinilazole demonstrated substantial clinical benefit over vancomycin. This included ridinilazole achieving statistical superiority over vancomycin in sustained clinical response (‘SCR’), a composite endpoint of cure at the end of treatment and no recurrence 30 days after treatment, a result which was driven by a large numerical reduction in infection recurrence.
“CDI is a serious disease that is a major healthcare challenge due to the high recurrence rates which are believed to be exacerbated by the broad spectrum antibiotics we use to treat CDI today,” Professor Mark Wilcox, University of Leeds and Principal Investigator in CoDIFy commented. “A highly selective antibiotic has the potential to transform the current treatment paradigm and keep recurrent CDI at bay. The ability of ridinilazole to provide a significant increase in sustained clinical responses compared with the standard of care in CoDIFy provides evidence that ridinilazole is highly selective and warrants its continued clinical development.”

Key results from CoDIFy published in The Lancet Infectious Diseases:

Ridinilazole achieved statistical superiority in sustained clinical response (‘SCR’) with rates of 66.7% compared with 42.4% for vancomycin.
Ridinilazole achieved a large numerical reduction in recurrent disease over vancomycin (14.3% recurrence with ridinilazole vs. 34.8% recurrence with vancomycin).
Ridinilazole met the pre-specified endpoint of non-inferiority on cure rates at the end of treatment (77.8% for ridinilazole vs. 69.7% for vancomycin).
Median time to resolution of diarrhoea favoured ridinilazole (four days on ridinilazole vs. five days on vancomycin) and numerically more subjects on ridinilazole had resolution of diarrhoea compared with vancomycin by day six (77.8% vs. 63.6%).
Median time to hospital discharge was five days for ridinilazole-treated subjects versus seven days for vancomycin-treated subjects.
Ridinilazole was retained in the gut, the site of infection, with negligible systemic exposure observed.
Adverse event profiles were similar between ridinilazole-treated and vancomycin-treated subjects, with no safety signals being identified with ridinilazole.
Mr Glyn Edwards, Chief Executive Officer of Summit, added: “The results of our CoDIFy trial provided further evidence of ridinilazole’s ability to address the key clinical issue of recurrence, which could lead to improved patient care and reduced economic burden of CDI. We are therefore planning to progress this novel programme into Phase 3 clinical trials. With ridinilazole, we believe we have a promising potential treatment option for this potentially fatal infectious disease.”

Ridinilazole is now being prepared for entry into a Phase 3 clinical programme that is expected to comprise two Phase 3 trials evaluating ridinilazole compared to vancomycin. The primary endpoint of the Phase 3 clinical trials is expected to be testing for superiority on sustained clinical response. The Phase 3 clinical trials are planned to start in the first half of 2018.

The publication reference is Lancet Infect Dis 2017; published online Apr 28:

[luminoso] 28/4/2017 23:53

Just got this in the mail.



Anyone else seen it ? Strange time to release. Will peruse over long week-end as I have had a few sherberts tonight.

[chrisatrdg] 28/4/2017 17:31

Extract from the Sarepta Question & Answer session today (page 9)

Chad Messer

Alright, yeah. Key question I get. So I – just one other small quick ones on your summit partnership. I've been expecting another payment for ezutromid in the first quarter. I know they've kind of changed when they're going to readout data on that. Just wondering what the story is when that might be expected to be owed to them?

Ed Kay

Yeah, Chad, so the payment is expected to be made towards the back end of the second quarter. It could potentially slip into the third quarter, but the likelihood is the back end of the second quarter. As a reminder it's a one-time payment, so it will not count for non-GAAP purposes. So it will just be a cash payment of roughly $22 million.

Link

[waterloo01] 28/4/2017 15:52

One day they will let us know what the next steps are re RDZ. Can't leave it much longer. I also rather hope we might get some 'gobby' boys on the trial and get some user feedback (it's open label so no placebo).

Till then.........

[hugus maximus] 28/4/2017 15:38

Thanks Waterloo. Meanwhile I guess the share price stumbles around in a cold wind waiting for summer proper!